Home Cart Sign in  
Chemical Structure| 550-24-3 Chemical Structure| 550-24-3

Structure of Embelin
CAS No.: 550-24-3

Chemical Structure| 550-24-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Embelin, a quinone isolated from the Japanese Ardisia herb, is an inhibitor of X-linked inhibitor of apoptosis (XIAP) with IC50 of 4.1 μM in a cell-free assay.

Synonyms: Emberine; NSC 91874; Embelic acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Embelin

CAS No. :550-24-3
Formula : C17H26O4
M.W : 294.39
SMILES Code : O=C1C(O)=C(CCCCCCCCCCC)C(C(O)=C1)=O
Synonyms :
Emberine; NSC 91874; Embelic acid
MDL No. :MFCD00016369
InChI Key :IRSFLDGTOHBADP-UHFFFAOYSA-N
Pubchem ID :3218

Safety of Embelin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • XIAP

    XIAP, IC50:4.1 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
BV-2 murine microglia cells 0.1–20 μM 10 min to 24 h Evaluated the protective effect of Embelin against cumene hydroperoxide-induced oxidative stress, showing that high concentrations of Embelin reduced ROS levels to basal levels after 24 h. PMC7278612
THP-1 human leukemic monocytes 0.1–20 μM 10 min to 24 h Evaluated the protective effect of Embelin against cumene hydroperoxide-induced oxidative stress, showing that high concentrations of Embelin reduced ROS levels to basal levels after 24 h. PMC7278612
MCF10A 25 and 50 μM 24 h To examine the effect of embelin on normal breast epithelial cells, showing that embelin did not downregulate the expression of cFLIPL. PMC8289868
H184B5F5/M10 25 and 50 μM 24 h To examine the effect of embelin on normal breast epithelial cells, showing that embelin did not downregulate the expression of cFLIPL. PMC8289868
MDA-MB-453 0-100 μM 24 h and 48 h To examine the cytotoxic impact of embelin on breast cancer cells, showing dose-dependent cytotoxicity within 0 to 50 μM concentration range. PMC8289868
MCF-7 0-100 μM 24 h and 48 h To examine the cytotoxic impact of embelin on breast cancer cells, showing dose-dependent cytotoxicity within 0 to 50 μM concentration range. PMC8289868
MDA-MB-231 0-100 μM 24 h and 48 h To examine the cytotoxic impact of embelin on breast cancer cells, showing dose-dependent cytotoxicity within 0 to 50 μM concentration range. PMC8289868
YD10B cells 10–300 μM 24 hours Embelin reduced the viability of YD10B cells in a dose-dependent manner. PMC6472881
SCC25 cells 10–300 μM 24 hours Embelin reduced the viability of SCC25 cells in a dose-dependent manner. PMC6472881
Ca9-22 cells 2.5–300 μM 24 hours Embelin exhibited anticancer activity against Ca9-22 cells, inducing autophagic and apoptotic cell death. PMC6472881
B16-F1 cells 5 µM 3 hours To assess the effect of Embelin on the viability of B16-F1 cells, results showed that Embelin had a minor effect on the viability of B16-F1 cells. PMC4023885
LS174T cells 5 µM 3 hours To assess the effect of Embelin on the viability of LS174T cells, results showed that Embelin had a minor effect on the viability of LS174T cells. PMC4023885
Human dermal microvascular endothelial cells (HDMECs) 5 µM 3 hours To assess the effect of Embelin on the viability of HDMECs, results showed that Embelin significantly reduced the viability of HDMECs. PMC4023885
Human umbilical vein endothelial cells (HUVECs) 5 µM 3 hours To assess the effect of Embelin on the viability of HUVECs, results showed that Embelin significantly reduced the viability of HUVECs. PMC4023885
Tumor tissue endothelial cells (TECs) 0.01, 0.1, 1.0, 10.0 µM 48 hours Embelin concentrations above 0.1 µM effectively induced the expression of VCAM1 and SELE genes, with stronger expression at higher concentrations. PMC7595596
Vero cells 54 µM 48 hours Treatment of HSV-1 virions with embelin significantly inhibited viral infection, with inhibition rates reaching 98.7-100%. PMC7922599
Vero cells 20 to 70 µM 56 hours Embelin is noncytotoxic to Vero cells at concentrations ranging from 20 to 70 µM, with cell proliferation ranging from 84.21% to 100%. PMC7922599
PDLSCs cells 5 μM Evaluate the effect of Embelin on osteogenic differentiation of PDLSCs. Results showed Embelin significantly upregulated osteogenic factors (ALP and OCN) and promoted mineralized nodule formation. PMC11425865
RAW264.7 cells 5 μM Evaluate the effect of Embelin on macrophage polarization. Results showed Embelin significantly upregulated M2 macrophage markers (CD206, TGF-β) and downregulated M1 macrophage markers (CD86, iNOS). PMC11425865
Acinetobacter baumannii 2-16 mg/ml Embelin restored meropenem activity against NDM-1-positive pathogens. PMC5789148
Escherichia coli 2-16 mg/ml Embelin restored meropenem activity against NDM-1-positive pathogens. PMC5789148
Klebsiella pneumoniae ATCC BAA-2146 1-64 mg/ml Embelin restored meropenem activity against NDM-1-positive pathogens. PMC5789148

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish (Danio rerio) Pentylenetetrazole (PTZ)-induced acute seizure model Intraperitoneal injection 0.078-10 mg/kg Single administration, observed for 10 minutes To evaluate the effectiveness of EMB against PTZ-induced seizures and its associated cognitive dysfunction. Results showed that EMB at doses of 0.156-0.625 mg/kg significantly reduced seizures and improved cognitive function. PMC6823247
Zebrafish (Danio rerio) Pentylenetetrazole (PTZ) kindling model Intraperitoneal injection 0.156-0.625 mg/kg Once daily for 10 days To evaluate the ameliorative effects of Embelin on chronic epilepsy and associated cognitive impairments induced by PTZ kindling model. Results showed that Embelin significantly reduced seizures and improved memory function, downregulated inflammatory markers, and increased neurotransmitter levels (GABA, Ach, and glutamate). PMC6478791
Sprague Dawley rats Scopolamine-induced Alzheimer’s disease-like condition Intraperitoneal injection 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg Once daily for 17 days To evaluate the nootropic and anti-amnesic effects of Embelin in scopolamine-induced amnesia rats. Embelin significantly improved the recognition index and memory retention in NOR and EPM tests and increased mRNA expression levels of BDNF, CREB1, SOD1, and CAT. PMC6026638
Wistar albino rats OVA-LPS-induced allergic asthma model Oral 12.5, 25 and 50 mg/kg Once daily for 15 days To evaluate the protective effect of Embelin against OVA-LPS-induced severe airway inflammation, results showed Embelin significantly inhibited inflammatory cell infiltration and Th2-mediated cytokine levels PMC8685448
C57BL/6 mice Pancreatic cancer model Intraperitoneal injection 4 µL Embelin (50 mg/mL in DMSO) Every 3 days for 30 days Embelin treatment significantly increased VCAM-1 and ICAM-1 expression in tumor tissues, promoted infiltration of CD3+ and CD8+ T cells, and inhibited tumor growth. PMC7595596
C57BL/6 mice Colitis-associated cancer (CAC) model Oral 50 mg/kg/day Daily, throughout the entire experiment To evaluate the effect of Embelin on the accumulation and function of MDSCs in the CAC model. Embelin significantly reduced the accumulation of MDSCs in the spleen and tumor tissue and impaired their immunosuppressive activity, leading to restored T cell responses. PMC6205065
Mouse PTEN-ZBTB7A and PTEN-TP53 double null models Oral 60 mg/kg 5 days per week for 4 weeks Embelin in combination with Bicalutamide significantly reduced tumor burden and proliferation rate PMC4126039
Mice B16-F1 melanoma and LS174T colon carcinoma xenograft models Intraperitoneal injection 8 mg/kg Every 48 hours for 3 weeks To assess the effect of Embelin on tumor growth and angiogenesis, results showed that Embelin significantly inhibited tumor growth and reduced microvessel density. PMC4023885
Mice Collagen antibody induced arthritis (CAIA) model Oral gavage low dose 30mg/kg/day, high dose 50mg/kg/day Once daily for 7 days Low dose Embelin significantly suppressed inflammation and bone erosion, reduced serum CTX-1 levels, and increased apoptotic cells PMC4539506

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02785172 Psoriasis Phase 2 Completed - United States, California ... More >> Valeant Site 12 Fullerton, California, United States, 92831 Valeant Site 04 La Mesa, California, United States, 91941 Valeant Site 03 San Diego, California, United States, 92093 Valeant Site 09 San Diego, California, United States, 92093 United States, Florida Valeant Site 05 Lauderdale Lakes, Florida, United States, 33313 Valeant Site 02 Miami, Florida, United States, 33111 United States, Minnesota Valeant Site 07 Fridley, Minnesota, United States, 55421 United States, North Carolina Valeant Site 08 Chapel Hill, North Carolina, United States, 27514 United States, Ohio Valeant Site 06 Columbus, Ohio, United States, 43085 United States, South Carolina Valeant Site 13 Mount Pleasant, South Carolina, United States, 29464 United States, Texas Valeant Site 11 Katy, Texas, United States, 77449 Valeant Site 10 San Antonio, Texas, United States, 78201 Valeant Site 01 Sugar Land, Texas, United States, 77479 United States, Utah Valeant Site 14 Salt Lake City, Utah, United States, 84103 Less <<
NCT03058744 Psoriasis Phase 1 Completed - United States, California ... More >> Valeant Site 12 Anaheim, California, United States, 92801 Valeant Site 05 Encino, California, United States, 91436 Valeant Site 01 San Diego, California, United States, 92093 Valeant Site 07 Santa Rosa, California, United States, 95401 United States, Florida Valeant Site 10 Orange Park, Florida, United States, 32065 Valeant Site 09 Sanford, Florida, United States, 32771 United States, Georgia Valeant Site 08 Atlanta, Georgia, United States, 30301 United States, Indiana Valeant Site 04 Plainfield, Indiana, United States, 46168 United States, New York Valeant Site 06 New York, New York, United States, 10001 United States, Pennsylvania Valeant Site 11 Philadelphia, Pennsylvania, United States, 19019 United States, Texas Valeant Site 03 Austin, Texas, United States, 73301 Valeant Site 02 Katy, Texas, United States, 77449 Less <<
NCT01567215 Fetus or Newborn Affected by C... More >>ondition of Umbilical Cord Less << Phase 2 Completed - Denmark ... More >> Hvidovre Hospital Kettegård Alle 31, Hvidovre, Denmark, 2650 Hvidovre University Hospital Hvidovre, Kettegård alle 30, Denmark, 2650 Less <<
NCT00544687 Healthy Phase 1 Completed - Germany ... More >> bioskin GmbH Hamburg, Germany Less <<
NCT00865605 Healthy Phase 1 Completed - United States, California ... More >> DermTech International San Diego, California, United States, 92128 Less <<
NCT00865267 Healthy Phase 1 Completed - United States, California ... More >> DermTech International San Diego, California, United States, 92128 Less <<
NCT00990561 - Completed - -
NCT00990561 Stable Plaque Psoriasis Phase 4 Completed - United States, California ... More >> UCSF Psoriasis and Skin Treatment Center San Francisco, California, United States, 94118 Less <<
NCT00803166 - Completed - -
NCT01166646 Plaque Psoriasis Phase 2 Completed - United States, California ... More >> Therapeutics Clinical Research San Diego, California, United States, 92123 United States, Michigan Michigan Center for Skin Care Research (dba Skin Care Research) Clinton Township, Michigan, United States, 48038 Somerset Skin Centre Troy, Michigan, United States, 48084 United States, North Carolina Dermatology, Laser & Vein Specialists of the Carolinas PLLC Charlotte, North Carolina, United States, 28207 United States, Texas DermResearch Inc. Austin, Texas, United States, 78759 Less <<
NCT01111123 - Completed - -
NCT00802958 - Completed - -
NCT01610596 Psoriasis Pla... More >>que Psoriasis Less << Phase 2 Completed - United States, California ... More >> Therapeutics Clinical Research San Diego, California, United States, 92123 United States, Minnesota Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432 United States, Texas DermResearch, Inc. Austin, Texas, United States, 78759 Less <<
NCT01567995 Eczema Phase 3 Completed - China, Jiangsu ... More >> GSK Investigational Site Nanjing, Jiangsu, China, 210029 GSK Investigational Site Nanjing, Jiangsu, China, 210042 China GSK Investigational Site Beijing, China, 100034 GSK Investigational Site Beijing, China, 100044 GSK Investigational Site Beijing, China, 100730 GSK Investigational Site Shanghai, China, 200040 GSK Investigational Site Tianjin, China, 300052 Less <<
NCT01111123 Plaque Psoriasis Phase 4 Completed - United States, New York ... More >> Icahn School of Medicine at Mount Sinai, Department of Dermatology New York, New York, United States, 10029 Less <<
NCT03212963 Plaque Psoriasis Phase 4 Recruiting December 2018 United States, Florida ... More >> Olympian Clinical Research Recruiting Clearwater, Florida, United States, 33756 Contact: Matthew Brent Zook, MD, PhD    813-849-5566       Contact: Dustin SIegert    813-849-5566    dsiegert@olympianresearch.com    Wisdom Clinical Research Institute, Corp. Recruiting Coral Gables, Florida, United States, 33134 Contact: Maria Carballosa, MD    305-443-3480       Contact: Dalila Diaz    305-443-3480    ddiaz@drmaritzafuentes.com    ASCLEPES Research Center Recruiting Spring Hill, Florida, United States, 34609 Contact: Imad Jandali, MD       kleonard@asclepes.com    Contact: Katie Leonard    352-364-9427    kleonard@asclepes.com Less <<
NCT03245385 Atopic Dermatitis Phase 2 Terminated(Sponsors decision) - United States, California ... More >> Providence Clinical Research North Hollywood, California, United States, 91606 Havana Research Institute Pasadena, California, United States, 91105 United States, Florida Vital Pharma Research Hialeah, Florida, United States, 33016 Solutions Through Advanced Research Jacksonville, Florida, United States, 32256 Integrity Research Center Miami, Florida, United States, 33015 Millennium Clinical Research, INC Miami, Florida, United States, 33125 Regenerate Clinical Trials, LLC Miami, Florida, United States, 33155 Life Medical Center and Research, INC Miami, Florida, United States, 33166 Vista Health Research Miami, Florida, United States, 33176 United States, Michigan Elias Research Troy, Michigan, United States, 48085 United States, Montana Montana Medical Research/Elias Research Assoc. Missoula, Montana, United States, 49808 United States, Pennsylvania L&C Professional Medical Research Institute Hazleton, Pennsylvania, United States, 18201 United States, Texas Sun Research Institute San Antonio, Texas, United States, 78215 Less <<
NCT03298581 Plaque Psoriasis Phase 2 Withdrawn(Sponsor decision) August 31, 2018 -
NCT01166646 - Completed - -
NCT02123966 Chronic Graft-versus-Host-Dise... More >>ase Oral Mucosal Disease Due to Graft-versus-host Disease Less << Phase 2 Terminated(Due to slow accrual... More >>, study team has decided to end the study early.) Less << - United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT02785185 Psoriasis Phase 2 Completed - United States, Arkansas ... More >> Valeant Site 05 Rogers, Arkansas, United States, 75758 United States, California Valeant Site 10 Beverly Hills, California, United States, 90210 Valeant Site 09 Carlsbad, California, United States, 92008 Valeant Site 13 Los Angeles, California, United States, 90045 Valeant Site 12 Santa Monica, California, United States, 90404 United States, Florida Valeant Site 07 Coral Gables, Florida, United States, 33134 Valeant Site 11 North Miami Beach, Florida, United States, 33162 Valeant Site 03 Sanford, Florida, United States, 32771 United States, Indiana Valeant Site 08 Albany, Indiana, United States, 47150 United States, Kentucky Valeant Site 04 Louisville, Kentucky, United States, 40202 United States, Minnesota Valeant Site 06 Fridley, Minnesota, United States, 55432 United States, North Carolina Valeant Site 02 High Point, North Carolina, United States, 27262 United States, Texas Valeant Site 01 Houston, Texas, United States, 77065 Less <<
NCT01610596 - Completed - -
NCT02123966 - Terminated(Due to slow accrual... More >>, study team has decided to end the study early.) Less << - -
NCT01870050 Lichen Simples Chronicus and P... More >>rurigo Less << Not Applicable Not yet recruiting November 2019 United States, Illinois ... More >> J H Stroger Hospital of Cook County Not yet recruiting Chicago, Illinois, United States, 60612 Contact: Joerg Albrecht, MD    312-864-4480    jalbrecht@cookcountyhhs.org    Principal Investigator: Joerg Albrecht          Sub-Investigator: Warren Piette, MD Less <<
NCT01313221 Psoriasis Phase 3 Completed - Canada, Alberta ... More >> Research Site Calgary, Alberta, Canada, T2G 1B1 Canada, British Columbia Research Site Surrey, British Columbia, Canada, V3R 6A7 Research Site Vancouver, British Columbia, Canada, V5Z 4E8 Canada, Manitoba Research Site Winnipeg, Manitoba, Canada, R3C 0N2 Canada, New Brunswick Research Site Moncton, New Brunswick, Canada, E1C 8X3 Canada, Newfoundland and Labrador Research Site St. John's, Newfoundland and Labrador, Canada, A1A 5E8 Research Site St. John's, Newfoundland and Labrador, Canada, A1C 2H5 Canada, Nova Scotia Research Site Halifax, Nova Scotia, Canada, B3H 1Z4 Canada, Ontario Research Site Courtice, Ontario, Canada, L1E 3C3 Research Site Markham, Ontario, Canada, L3P 1A8 Research Site Mississauga, Ontario, Canada, L5H 1G9 Research Site North Bay, Ontario, Canada, P1B 3Z7 Research Site Peterborough, Ontario, Canada, K9J 1Z2 Research Site Richmond Hill, Ontario, Canada, L4B 1A5 Research Site Sudbury, Ontario, Canada, P3C 1X8 Research Site Toronto, Ontario, Canada, M3H 5Y8 Research Site Toronto, Ontario, Canada, M4V 1R1 Research Site Waterloo, Ontario, Canada, N2J 1C4 Research Site Windsor, Ontario, Canada, N8W 5L7 Canada, Quebec Research Site Montreal, Quebec, Canada, H2K 4L5 Research Site Montreal, Quebec, Canada, H3Z 2S6 Research Site Saint-Hyacinthe, Quebec, Canada, J2S 6L6 Canada Research Site Quebec, Canada, G1J 1X7 Research Site Quebec, Canada, G1V 4X7 Less <<
NCT03089775 Contact Dermatitis Phase 1 Completed - Canada, Quebec ... More >> Innovaderm Research Inc. Montreal, Quebec, Canada, H2K 4L5 Less <<
NCT03758365 Vasoconstriction Phase 1 Recruiting January 15, 2019 France ... More >> CPCAD Recruiting Nice, France, 06200 Contact: Catherine Queille-Roussel, MD Less <<
NCT03399526 Psoriasis Phase 1 Completed - Germany ... More >> Hamburg, Germany, 20095 Less <<
NCT00457288 Cutaneous Mastocytosis Phase 2 Completed - Germany ... More >> Klinik und Poliklinik für Dermatologie und Venerologie der Universität Köln, Germany, D-50924 Universitäts-Hautklinik Mainz, Germany, D-55131 Klinik und Poliklinik für Dermatologie und Allergologie der LMU München, Germany, D-80337 Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein der TU München, Germany, D-80802 Less <<
NCT01313221 - Completed - -
NCT02355639 Skin and Connective Tissue Dis... More >>eases Less << Phase 1 Completed - Germany ... More >> Charité - Universitaetsmedizin Berlin, Department of Dermatology and Allergy Berlin, Germany, 10117 Less <<
NCT02940002 Psoriasis Phase 1 Completed - Germany ... More >> Schwerin, Mecklenburg-Vorpommern, Germany, 19055 Bochum, Nordrhein-Westfalen, Germany, 44803 Hamburg, Germany, 20095 Less <<
NCT01946386 Psoriasis Vulgaris Phase 1 Completed - France ... More >> CPCAD, Centre de Pharmacologie Clinique Appliquée à la Dermatologie Nice, France, 06202 Less <<
NCT02445807 Chronic Stable Plaque Psoriasi... More >>s Less << Phase 3 Completed - -
NCT02392130 Skin Tissue Diseases ... More >> Connective Tissue Diseases Less << Phase 1 Completed - Germany ... More >> bioskin GmbH Hamburg, Germany, 20095 Less <<
NCT02635204 - Completed - -
NCT02376049 Atopic Dermatitis Phase 1 Completed - Canada, Quebec ... More >> Innovaderm Research Inc. Montreal, Quebec, Canada, H2K 4L5 Israel Beit Harofim Netanya, Israel, 42701 Less <<
NCT03584360 Psoriasis Vulgaris Phase 2 Not yet recruiting June 2019 -
NCT02635204 Psoriasis Phase 3 Completed - -
NCT02973776 Psoriasis Vulgaris Phase 1 Completed - France ... More >> CPCAD Nice, Cedex, France, 06202 Less <<
NCT02487212 Hypertrophic Scars Phase 4 Completed - Thailand ... More >> Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok, Thailand, 10700 Less <<
NCT00769184 - Completed - -
NCT02445807 - Completed - -
NCT02492373 Lentigines Po... More >>st Inflammatory Hyperpigmentation Less << Not Applicable Completed - Thailand ... More >> Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok, Thailand, 10700 Less <<
NCT00769184 Psoriasis Not Applicable Completed - United States, New Jersey ... More >> Windsor Dermatology East Windsor, New Jersey, United States, 08520 Less <<
NCT03535233 Alopecia Areata Phase 4 Completed - -
NCT00779792 Dermatitis, Contact ... More >> Dermatitis, Occupational Less << Phase 4 Unknown November 2008 Denmark ... More >> Department of Dermatology, Odense University Hospital Odense, Denmark, 5000 Less <<
NCT02680717 Scleroderma Phase 1 Withdrawn(Unable to obtain IRB... More >> approval at all sites) Less << May 2017 -
NCT01987076 Drug Rash With Eosinophilia an... More >>d Systemic Symptoms Less << Not Applicable Unknown October 2016 France ... More >> Henri Mondor Hospital Recruiting Creteil, France, 94010 Contact: Olivier CHOSIDOW, MD, PhD    (0)149812501 ext +33    olivier.chosidow@hmn.aphp.fr    Contact: Laetitia GREGOIRE, M.Sc    (0)149814164 ext +33    laetitia.gregoire@hmn.aphp.fr    Principal Investigator: Olivier CHOSIDOW, MD, PhD Less <<
NCT02936492 Psoriasis Phase 1 Terminated - Germany ... More >> Hamburg, Germany, 20251 Less <<
NCT01407471 Cutaneous Atrophy Due to Corti... More >>costeroids Less << Phase 2 Completed - France ... More >> Bichat Hospital Paris, France, 75877 Less <<
NCT02313870 Bullous Pemphigoid Phase 3 Unknown December 2015 France ... More >> University Hospital Of Montpellier Recruiting Montpellier, France, 34295 Contact: Olivier Dereure, MD, PhD    04 67 33 69 06 ext +33    o-dereure@chu-montpellier.fr    Principal Investigator: Olivier Dereure, MD, PhD Less <<
NCT01381445 Dermatitis, Atopic Phase 1 Completed - Germany ... More >> GSK Investigational Site Berlin, Germany, 10117 Less <<
NCT01591785 Hand Eczema F... More >>oot Eczema Less << Not Applicable Completed - United States, New York ... More >> Mount Sinai School of Medicine New York, New York, United States, 10029 Less <<
NCT00102557 Lichen Planus, Oral Phase 2 Completed - United States, Maryland ... More >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Less <<
NCT03386643 Oral Lichen Planus Phase 2 Active, not recruiting December 6, 2018 Brazil ... More >> School of Dentistry of Ribeirão Preto, University of São Paulo Ribeirão Preto, São Paulo, Brazil, 14040-904 Less <<
NCT00655512 Healthy Phase 1 Completed - Germany ... More >> Department of Dermatology, Medical Faculty, TU Dresden Dresden, Germany Less <<
NCT03286582 Bullous Pemphigoid Phase 2 Recruiting May 2019 Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Chia-Yu Chu, Dr. Less <<
NCT02733874 Psoriasis Phase 4 Completed - -
NCT02368886 Colon Adenocarcinoma ... More >> Rectal Adenocarcinoma Stage III Colorectal Cancer AJCC v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Less << Phase 2 Active, not recruiting June 22, 2019 -
NCT01400022 Vulvar Lichen Sclerosus Not Applicable Completed - Germany ... More >> Department of Dermatology, Ruhr University Bochum Bochum, NRW, Germany, 44791 Less <<
NCT01235442 Psoriasis Phase 3 Completed - -
NCT01235442 - Completed - -
NCT00470392 Psoriasis Not Applicable Terminated(Recruiting complete... More >> and administrative termination) Less << - United States, Ohio ... More >> University Hospital Case Medical Center Cleveland, Ohio, United States, 44106 VA Medical Center, Cleveland Cleveland, Ohio, United States, 44106 Less <<
NCT01043224 Psoriasis Vulgaris Phase 1 Completed - France ... More >> LEO Pharma site Nice, France, 06202 Less <<
NCT03320460 Lichen Planus, Oral ... More >> Low-Level Light Therapy Less << Not Applicable Not yet recruiting December 2020 -
NCT00438399 Scalp Psoriasis Phase 3 Completed - Italy ... More >> Clinica Dermatologica Azienda Ospedaliera Policlinico di Modena Modena, Italy, 41100 Less <<
NCT00438399 - Completed - -
NCT00715975 Psoriasis Phase 2 Phase 3 Completed - Brazil ... More >> Lal Clinica Valinhos, Sao Paulo, Brazil, 13270000 Less <<
NCT02360202 Bullous Pemphigoid Phase 4 Recruiting December 2017 France ... More >> Rouen University Hospital Recruiting Rouen, France, 76031 Contact: Sophie Duvert Lehembre, MD Less <<
NCT01453686 Alopecia Areata Phase 3 Completed - Canada, Ontario ... More >> The Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Less <<
NCT00862654 Scalp Seborrheic Dermatitis Phase 3 Completed - Belgium ... More >> Galderma Investigational Center Brugge, Belgium Galderma Investigational Center Bruxelles, Belgium Galderma Investigational Center Geel, Belgium Galderma Investigational Center Gent, Belgium Galderma Investigational Center Liege, Belgium Galderma Investigational Center Mons, Belgium France Galderma Investigational Center Paris, France Germany Galderma Investigational Center Berlin, Germany Galderma Investigational Center Bonn, Germany Galderma Investigational Center Hamburg, Germany Galderma Investigational Center Lubeck, Germany Galderma Investigational Center Mahlow, Germany Galderma Investigational Center Wuppertal, Germany Korea, Republic of Galderma Investigational Center Seoul, Korea, Republic of Mexico Galderma Investigational Center Guadalajara, Mexico Galderma Investigational Center Mexico, Mexico Galderma Investigational Center Naucalpan, Mexico Galderma Investigational Center Zapopan, Jalisco, Mexico Less <<
NCT03592342 Oral Lichen Planus Phase 2 Recruiting March 31, 2019 United States, Massachusetts ... More >> Tufts University, School of Dental Medicine Recruiting Boston, Massachusetts, United States, 02111 Contact: Athena Papas, DMD    617-636-3931    Athena.Papas@tufts.edu    Brigham and Women's Hospital, Division of Oral Medicine and Dentistry Recruiting Boston, Massachusetts, United States, 02115 Contact: Vidya Sankar, DMD, MHS    617-525-8412    vsankar@bwh.harvard.edu    United States, New York NYU College of Dentistry, Bluestone Center for Clinical Research Recruiting New York, New York, United States, 10010 Contact: Alexander R Kerr, DDS, MSD    347-721-7506    ark3@nyu.edu    United States, North Carolina UNC Dermatology and Skin Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27516 Contact: Donna Aline Culton, MD    +1 984 974 3669    donna_culton@med.unc.edu    Contact: Natasha Marvi, Study Coordinator    +1 984 974 3670    natasha_marvi@med.unc.edu    Carolinas Center for Oral Health Recruiting Charlotte, North Carolina, United States, 28209 Contact: Joul J Napenas, DDS    704-512-2110    joel.napenas@atriumhealth.org    Wake Forest University, Health Sciences Dept. of Dermatology Recruiting Winston-Salem, North Carolina, United States, 27104 Contact: William Huang, MD, MPH    336-716-3775    whuang@wakehealth.edu    United States, Pennsylvania University of Pennsylvania Health System, Dept. Oral amd Maxillofacial Surgery Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Thomas P Sollecito, DMD    215-898-6627    tps@upenn.edu    United States, Texas Texas A&M University (TAMU), College of Dentistry Not yet recruiting Dallas, Texas, United States, 75246 Contact: Paras B Patel, DDS    214-828-8116    ppatel10@tamhsc.edu    UT Southwestern Medical Center Department of Surgery Not yet recruiting Dallas, Texas, United States, 75390-9109 Contact: Thomas Schlieve, DDS, MD    214-648-3034    Thomas.Schlieve@UTSouthwestern.edu    Canada, Alberta Kaye Edmonton Clinic Not yet recruiting Edmonton, Alberta, Canada, T6G1Z1 Contact: Tim McGraw, D.D.S    +1-780 492-5195    wmcgaw@ualberta.ca    Contact: Breanne Stewart, Coordinator    +1-780-974-8606    breanne1@ualberta.ca    Canada, Ontario Health Sciences North, North East Cancer Center Recruiting Sudbury, Ontario, Canada, P3E5JL Contact: Debbie Saunders, D.D.S    +1-705 523-7334    dsaunders@hsnsudbury.ca    Contact: Pamela Leduc, Coordinator    +1-705-523-7300 ext 1923       Denmark Rigshospitalet Recruiting Copenhagen, Denmark, 2100 Contact: Morten Schiødt, DDS, Dr    +45 3545 1880    morten.schioedt@regionh.dk    Germany Universitätsklinikum Bonn (AöR), Klinik und Poliklinik für Dermatologie und Allergologie Recruiting Bonn, Germany, 53127 Contact: Thomas Bieber, Prof Dr Med    +49 (0)228 287 16811    Thomas.Bieber@ukb.uni-bonn.de    LMU München, Klinik und Poliklinik für Dermatologie und Allergologie Recruiting Munich, Germany, 80337 Contact: Thomas Ruzicka, Prof Dr Med    +49 (0)89 44005 60051    Thomas.Ruzicka@med.uni-muenchen.de    Ireland Cork University Dental School and Hospital Not yet recruiting Cork, Ireland, T12 E8YV Contact: Christine McCreary, Dr    +353 (0)21 4901105    C.McCreary@ucc.ie    Dublin Dental University and Hospital Trinity College Dublin Not yet recruiting Dublin, Ireland, D02 F589 Contact: Claire Healy, Dr    + 353 1 612 7314    claire.healy@dental.tcd.ie    United Kingdom Leeds Dental Institute Not yet recruiting Leeds, United Kingdom, LS9 9LU Contact: Alan Mighell, Dr    +44 (0)113 343 6121    A.J.Mighell@leeds.ac.uk    King´s College London Dental Institute, Oral Clinical Research Unit Recruiting London, United Kingdom, SE1 9RT Contact: Richard Cook, Dr    +44 (0)20 78485958    richard_james.cook@kcl.ac.uk    University College London and University College London Hospitals Trust Recruiting London, United Kingdom, WC1X 8LD Contact: Stefano Fedele, Dr    +44 (0)20 3456 1004    s.fedele@ucl.ac.uk    University of Sheffield, School of Clinical Dentistry Recruiting Sheffield, United Kingdom, S10 2TA Contact: Anne Hegarty, Dr    +44 (0)114 2268669    anne.hegarty@sth.nhs.uk Less <<
NCT00297011 Herpes Labialis Phase 2 Completed - United States, Utah ... More >> University of Utah Salt Lake City, Utah, United States, 84132 Less <<
NCT00470392 - Terminated(Recruiting complete... More >> and administrative termination) Less << - -
NCT00862654 - Completed - -
NCT00393263 Lichen Sclerosus Phase 2 Completed - United States, District of Col... More >>umbia Center for VulvoVaginal Disorders Washington, District of Columbia, United States, 21012 Less <<
NCT02416531 Vulvar Lichen Sclerosus Not Applicable Completed - Brazil ... More >> Hospital Pérola Byington São Paulo, SP, Brazil, 01314000 Less <<
NCT01126255 Vulvar Lichen Sclerosus Phase 2 Terminated(Recruitment problem... More >>s) Less << - Switzerland ... More >> Dep. of Obstetrics and Gynecology, Bern University Hospital Bern, Switzerland, 3010 Less <<
NCT00400725 Scalp Psoriasis Phase 3 Completed - Canada ... More >> centre de Recherche Dermatologique du Québec Quebec, Canada Less <<
NCT01323673 - Completed - -
NCT00437255 Plaque Psoriasis Phase 4 Completed - United States, Minnesota ... More >> Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432 United States, Texas DermResearch, Inc. Austin, Texas, United States, 78759 J & S Studies, Inc. Bryan, Texas, United States, 77802 Baylor Research Institute Dallas, Texas, United States, 75230 Less <<
NCT00803439 - Completed - -
NCT01205880 Psoriasis Phase 4 Completed - United States, New York ... More >> Mount Sinai School of Medicine New York, New York, United States, 10029 Less <<
NCT01323673 Dermatitis, Chronic Phase 4 Completed - United States, California ... More >> GSK Investigational Site San Diego, California, United States, 92123 United States, Florida GSK Investigational Site Boynton Beach, Florida, United States, 33437 GSK Investigational Site West Palm Beach, Florida, United States, 33401 United States, Kentucky GSK Investigational Site Louisville, Kentucky, United States, 40202 GSK Investigational Site Louisville, Kentucky, United States, 40217 United States, New Jersey GSK Investigational Site Belleville, New Jersey, United States, 07109 GSK Investigational Site Montclair, New Jersey, United States, 07042 United States, Tennessee GSK Investigational Site Knoxville, Tennessee, United States, 37922 GSK Investigational Site Nashville, Tennessee, United States, 37215 United States, Texas GSK Investigational Site Austin, Texas, United States, 78759 Less <<
NCT03026478 Oral Lichen Planus Phase 2 Recruiting June 2018 India ... More >> Komali Garlapati Recruiting Hyderabad, Telangana, India, 500060 Contact: KOMALI GARLAPATI, M.D.S.    +918008884945    komali_garlapati@yahoo.co.in Less <<
NCT00437216 - Completed - United States, New Jersey ... More >> DHC Dimensional HealthCare, Inc. (Clinical Research Organization) Cedar Knolls, New Jersey, United States, 76117 Less <<
NCT01012713 - Completed - -
NCT00757874 Vulvar Lichen Sclerosus Phase 2 Completed - Canada, Quebec ... More >> CHU Sainte-Justine Montreal, Quebec, Canada, H3P 3N5 Less <<
NCT02744378 Oral Lichen Planus Phase 2 Completed - -
NCT01012713 Chronic Stable Plaque Psoriasi... More >>s Less << Phase 4 Completed - United States, California ... More >> UCSF Psoriasis and Skin Treatment Center San Francisco, California, United States, 94118 Less <<
NCT00436540 Psoriasis Phase 4 Completed - United States, California ... More >> Solano Clinical Research Vallejo, California, United States, 94589 United States, Missouri Central Dermatology, PC St. Louis, Missouri, United States, 63117 Less <<
NCT03453190 Psoriasis Phase 4 Recruiting June 30, 2020 United States, Maryland ... More >> Washington Dermatology Center Recruiting Rockville, Maryland, United States, 20852 Contact: Vicki Smith    301-984-3000    wdcderm22@gmail.com    Contact: Ronald Prussick, M.D.    3019843000    drprussick@aol.com    Principal Investigator: Ronald Prussick, MD Less <<
NCT00658788 Psoriasis Phase 3 Completed - United States, California ... More >> Therapeutics Clinical Research San Diego, California, United States, 92123 United States, Georgia MedaPhase, Inc. Newnan, Georgia, United States, 30263 Gwinnett Clinical Research Center, Inc Snellville, Georgia, United States, 30078 United States, Indiana Hudson Dermatology Evansville, Indiana, United States, 47714 United States, New York Mount Sinai Department of Dermatology New York, New York, United States, 10029 United States, Ohio Northeastern Ohio Universities College of Medicine Warren, Ohio, United States, 44483 United States, Oklahoma Central Sooner Research Norman, Oklahoma, United States, 73069 United States, Texas J&J Studies, Inc College Station, Texas, United States, 77840 Suzanne Bruce and Associates, PA Houston, Texas, United States, 75390 United States, Virginia Virginia Clinical Research, Inc Norfolk, Virginia, United States, 23507 United States, Washington Dermatology Associates of Seattle, PLLC Seattle, Washington, United States, 98101 United States, Wisconsin Madison Skin and Research, Inc Madison, Wisconsin, United States, 53719 Less <<
NCT02131324 - Completed - -
NCT01111981 Alopecia Phase 4 Unknown October 2010 United States, Maryland ... More >> Callender Center for Clinical Research Recruiting Mitchellville, Maryland, United States, 20721 Contact: Lynn Carter, BA    301-249-0970    clinresearch@callenderskin.com    Contact: Niccole Mathews    301-249-0970    clinresearch@callenderskin.com Less <<
NCT01699412 Graft vs Host Disease ... More >> Oral Manifestations Less << Phase 3 Completed - Brazil ... More >> Hematology and Hemotherapy Center Campinas, São Paulo, Brazil, 13083-878 Clementino Fraga Filho University Hospital Rio de Janeiro, Brazil, 21941-913 Less <<
NCT00881868 Scalp Psoriasis Phase 4 Completed - United States, California ... More >> Dermatology Research Associates Los Angeles, California, United States, 90045 United States, Indiana Hudson Dermatology Evansville, Indiana, United States, 47714 United States, New York Research Division of The Skin Specialty Group New York, New York, United States, 10155 United States, Washington Dermatology Associates, PLLC Seattle, Washington, United States, 98101 Less <<
NCT00881868 - Completed - -
NCT00828464 Hand Dermatosis Phase 4 Completed - United States, Kentucky ... More >> Physicians Skin Care Louisville, Kentucky, United States, 40217 Less <<
NCT00828464 - Completed - -
NCT00864500 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042-4712 Less <<
NCT00658788 - Completed - -
NCT00852761 - Completed - -
NCT00864240 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042-4712 Less <<
NCT02131324 Psoriasis Phase 2 Completed - United States, Arizona ... More >> Advanced Research Associates Glendale, Arizona, United States, 85308 Agave Clinical Research, LLC Mesa, Arizona, United States, 85202 United States, California T. Joseph Raoof, MD, Inc. Encino, California, United States, 91436 United States, Florida International Dermatology Research, Inc. Miami, Florida, United States, 33144 FXM Research Corp. Miami, Florida, United States, 33175 FXM Research Miramar Miramar, Florida, United States, 33027 Belleair Research Pinellas Park, Florida, United States, 33781 Forward Clinical Trials Tampa, Florida, United States, 33624 United States, Georgia Marietta Dermatology Clinical Research, Inc. Marietta, Georgia, United States, 30060 United States, Kentucky Determatology Specialists Research, LLC Louisville, Kentucky, United States, 40202 United States, Nebraska Quality Clinical Research, Inc. Omaha, Nebraska, United States, 68114 United States, North Carolina Dermatology Consulting Services High Point, North Carolina, United States, 27262 United States, Oklahoma Lynn Health Science Institute Oklahoma City, Oklahoma, United States, 73112 United States, Rhode Island Clinical Partners, LLC Johnston, Rhode Island, United States, 02919 United States, South Carolina Radiant Research, Inc. Greer, South Carolina, United States, 29650 Less <<
NCT01893567 Plaque Psoriasis Phase 4 Completed - United States, Michigan ... More >> Hamzavi Dermatology Fort Gratiot, Michigan, United States, 48059 Less <<
NCT01557517 Oral Chronic Graft vs Host Dis... More >>ease Less << Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00852761 Plaque-Type Psoriasis Phase 4 Completed - United States, North Carolina ... More >> Wake Forest University Health Sciences Department of Dermatology Winston-Salem, North Carolina, United States, 27157 Less <<
NCT01893567 - Completed - -
NCT01745133 Psoriasis Phase 4 Completed - United States, Kentucky ... More >> DermResearch, PLLC Louisville, Kentucky, United States, 40217 Less <<
NCT02319616 Toxic Epidermal Necrolysis Phase 1 Phase 2 Active, not recruiting July 2019 United States, California ... More >> University of California, Davis Department of Dermatology Sacramento, California, United States, 95816 Less <<
NCT01745133 - Completed - -
NCT00988637 Plaque Psoriasis Phase 4 Completed - United States, California ... More >> Dermatology Research Associates Los Angeles, California, United States, 90045 Therapeutics Clinical Research San Diego, California, United States, 92123 United States, Indiana Hudson Dermatology Evansville, Indiana, United States, 47714 United States, Minnesota Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432 United States, Texas Baylor Research Institute Dermatology Research Dallas, Texas, United States, 75246 Canada, Ontario Probity Medical Research Waterloo, Ontario, Canada, N2J1C4 Less <<
NCT00733954 Plaque Psoriasis Phase 4 Completed - United States, California ... More >> East Bay Dermatology Medical Group, Inc. Fremont, California, United States, 94538 Solano Clinical Research Vallejo, California, United States, 94589 United States, Michigan Henry Ford Medical Center Detroit, Michigan, United States, 48202 United States, Minnesota Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432 United States, New York Dermatology Associates of Rochester Rochester, New York, United States, 14623 United States, Texas Baylor Research Institute - Dermatology Research Dallas, Texas, United States, 75246 Less <<
NCT00842153 Psoriasis Phase 4 Completed - United States, California ... More >> Center for Dermatology, Cosmetic and Laser Fremont, California, United States, 94538 United States, Kentucky Dermatology Specialists Louisville, Kentucky, United States, 40202 Less <<
NCT00842153 - Completed - -
NCT01703325 Psoriatic Nails Phase 4 Completed - Thailand ... More >> Siriraj Hospital Bangkok, Thailand, 10700 Less <<
NCT00733954 - Completed - -
NCT00988637 - Completed - -
NCT02573883 Vulvar Lichen Sclerosus Phase 3 Recruiting September 2019 United States, District of Col... More >>umbia Medstar Washington Hospital Center Lafayette Office Recruiting Washington, District of Columbia, United States, 20010 Contact: Cheryl B Iglesia, MD    202-877-6526    Cheryl.Iglesia@medstar.net    Contact: Patricia Tanjutco    (202)877-6526    Joanna.l.peterson@medstar.net    Sub-Investigator: Linda S Burkett, MD          Sub-Investigator: Andrew I Sokol, MD          Sub-Investigator: Amy J Park, MD          Sub-Investigator: Robert E Gutman, MD          Sub-Investigator: Lee A Richter, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.40mL

0.68mL

0.34mL

16.98mL

3.40mL

1.70mL

33.97mL

6.79mL

3.40mL

References

 

Historical Records

Categories